Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash from Operations (2020 - 2022)

Historic Cash from Operations for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$21.5 million.

  • Atea Pharmaceuticals' Cash from Operations rose 7143.44% to -$21.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$121.0 million, marking a year-over-year decrease of 3905.18%. This contributed to the annual value of -$135.5 million for FY2024, which is 5867.32% down from last year.
  • Atea Pharmaceuticals' Cash from Operations amounted to -$21.5 million in Q4 2022, which was up 7143.44% from -$21.2 million recorded in Q3 2022.
  • In the past 5 years, Atea Pharmaceuticals' Cash from Operations registered a high of $318.5 million during Q4 2020, and its lowest value of -$75.4 million during Q4 2021.
  • Moreover, its 3-year median value for Cash from Operations was -$17.1 million (2021), whereas its average is $7.4 million.
  • Data for Atea Pharmaceuticals' Cash from Operations shows a peak YoY increase of 33840.31% (in 2021) and a maximum YoY decrease of 27349.16% (in 2021) over the last 5 years.
  • Atea Pharmaceuticals' Cash from Operations (Quarter) stood at $318.5 million in 2020, then tumbled by 123.68% to -$75.4 million in 2021, then surged by 71.43% to -$21.5 million in 2022.
  • Its Cash from Operations stands at -$21.5 million for Q4 2022, versus -$21.2 million for Q3 2022 and -$19.2 million for Q2 2022.